PCSK9 and coronary atherosclerosis: In this study, quantitative coronary angiography was used to compare the area stenosis of nontarget lesions at baseline and 1 year after PCSK9 inhibition to determine the effect PCSK9 inhibition on coronary atherosclerosis regression of nontarget lesions after PPCI in ACS patients treated in combination with the standard statin therapy.